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So far, a number of publications have demonstrated the potential of direct injection of genes into the myocardium. [1] [2] [3] [4] [5] [6] [7] This may seem an attractive approach as it avoids complicated and expensive ex vivo manipulations followed by in vivo cell or organ grafting. However, direct injection into the myocardium results in gene expression over a limited region due to the lack of diffusion of the vector and, furthermore, it also results in local tissue damage which makes it a rather inappropriate therapeutic approach. 4, 8, 9 Intravascular gene delivery has raised higher hopes since the myocardium has a high density of capillaries. 10, 11 Indeed, as opposed to single shot injection, it has been proved that coronary infusion allows some diffusion of reporter genes to the myocardium. However, at the present state of our knowledge, the efficiency of this strategy appears to be still limited by various factors such as a low permeability of the capillaries to large molecules or particles due to their continuous non-fenestrated endothelium, or to the need for high perfusion pressure or because of a limited time contact of the vector with the target cell. 12 Moreover, Wright et al 13 pointed out that intracoronary infusion of cationic liposomes can result in multiple microinfarction.
In view of these difficulties, we have developed an alternative approach for myocardial gene transfer which is based on local delivery of the therapeutic gene into the pericardium.
The pericardial envelope of the heart may be used to overcome some of the restrictions inherent in other transfer methods. First, access to the pericardium can be obtained through rather simple procedures. Second, since the pericardium has a closed cavity, this may be used to maintain a prolonged contact time with the genetic vectors. The drawback of this approach is that the pericardial envelope appears to be rather tight, however, we will show that diffusion across this membrane can be increased by various pharmacological agents. Using this simple procedure, we show that significant territories of the myocardium can be transduced by adenoviral vectors.
Adult male Wistar rats were injected with a ⌬E1-recombinant adenoviral vector containing a CMV-driven bacterial ␤-galactosidase gene without a nuclear localization signal. 14 We used adenovirus since it has proven to be a rather reliable vector for gene transfer into the heart muscle due to its ability to infect nondividing cells, an absolute requirement for terminally differentiated cardiac myocytes. 9 Intra-pericardial injections were performed through a small incision of the abdominal wall below the xyphoid appendix, with a trans-diaphragmatic approach. Delivery of adenoviral vectors into the pericardium can be performed safely under visual control. Seven days after the injection, the animals were killed and their hearts as well as other organs (lungs, diaphragm, liver, kidney, spleen) were harvested. Serial frozen sections were performed and assayed for ␤-galactosidase activity. X-gal (5-bromo-4-chloro-3-indolyl-␤-d-galactoside) staining was observed almost exclusively in the pericardial cell layers (Figure 1 ). Only rarely were myocardial cells found to be transduced by the adenovirus (Figure 1b) . No significant staining was found either in the lungs or the diaphragm (data not shown). The same observation was also true for organs at the abdominal level, such as the liver, spleen or kidneys. Hence, the pericardium appears to be transduced by adenoviral vectors, but it also proves to be a tight envelope around the heart which allows no significant transduction of the myocardium. A similar observation was made by another group. 15 tightly joined cells limiting diffusion across this anatomical barrier. Moreover, the connective tissue layers found in the cardiac muscle most probably diminish the spread and overall infectivity of vectors. [16] [17] [18] Various strategies have been described to circumvent this problem. Lamping et al 15 showed that pre-treatment with tetracycline did increase ventricular myocyte transfection, possibly through the induction of an inflammatory process which could have increased a vector uptake at the level of the epicardium. Interestingly, Aoki et al 19 have reported myocardial transfection after injection within the pericardium of a hemagglutinating virus of Japan (HVJ)-liposome complex. However, their data only showed transfection in a limited area of the myocardium which extended through few surface layers. Transfected cells included cardiac myocytes and fibroblasts beneath the pericardium and some myocytes in the middle of the myocar-a b c
Figure 2 Intrapericardial vector delivery in the presence of proteolytic enzymes improves gene transfer. Serial cryosections demonstrate the extent of X-gal staining of the myocardium. (a) A typical transverse section shows that most transduced myocytes are found in the left ventricle (inferior wall and part of the lateral wall) and the interventricular septum. The right ventricle is only partly transfected. (b) A longitudinal section confirms the transfected area extending from the basis to the apex. (c) Microscopic analysis demonstrates that X-gal staining concerns essentially cardiac myocytes, even though staining is not homogeneous (magnification ×100).
dium around the vasa vasorum. 19 However, such treatment still remains inefficient.
We used a different strategy and reasoned that a loosening of the pericardial barrier might allow the virus to spread into the myocardium. To achieve this, we tested the possibility of interfering with some of the molecules which constitute this barrier. Among the various components of the extracellular matrix which composes the cardiac interstitium, molecules of collagen type I and type III are important. Thus, as a first step, we tested whether increasing concentrations of collagenase could improve diffusion of the recombinant adenovirus following injection in the pericardium. High doses of collagenase (over 2 mg) appeared to be lethal after a few days and we established that the maximal tolerable dose had to be less than 2 mg for an adult rat. However, under these conditions, transfection of cardiac myocytes remained poor and still limited to the immediate layer underlying the pericardium (data not shown).
Another major component of the extracellular matrix is hyaluronic acid and so we tested the effect of injecting increasing concentrations of hyaluronidase ranging from 1 to 700 units. Even at the highest doses, this enzyme was totally inefficient in facilitating gene transfer to the myocardium across the pericardial barrier (data not shown).
However, when both enzymes were used in conjunction, a different picture emerged. As shown in Figure 2 , optimized concentrations of collagenase (1 mg) and hyaluronidase (500 U), when injected together with the recombinant adenovirus, allow the virus to diffuse in the myocardium. In particular, a longitudinal section of the heart (Figure 2(b) ) clearly indicates that ␤-galactosidase expression is distributed from the base down to the apex. There is, however, a restriction in the distribution of the expressed gene since transfection mostly concerned the anterior wall of the left ventricle, the interventricular septum, part of the lateral wall of the left ventricle and part of the right ventricle (Figure 2a) . Figure 2c clearly indicates that the cardiac myocytes express the reporter gene. It is also noteworthy that no inflammatory reaction could be found in the transfected area at the time of death.
For comparison, the subdiaphragmatic approach was used to perform direct intracardiac injection. Injection volume had to be adjusted to a maximum volume of 100 l since injections of larger volumes induce cardiac arrest. Animals were killed at day 7 after injection and transverse cryosections of the heart were assayed for ␤-galactosidase activity. X-gal staining was measured in order to quantify the transfection area. The adenovirustransduced cardiac tissue area ranged from 1.4 to 3.9% of the total section. Figure 3 demonstrates the limited extent of the transfection area after direct injection into the left ventricular wall. These results are in close agreement with previously published data by other authors. 9, 20 To validate further the harmlessness of our injection procedure, a number of measurements were made. First, at the time of death, virus-injected animals had similar body weights when compared with control animals injected with identical enzyme solutions but lacking the adenovirus, and with untreated animals. Second, the heart weight/body weight ratios did not differ in any significant way between rats injected with recombinant adenovirus (2.94 ± 0.85 mg/g, n = 15) and sham operated animals (2.81 ± 0.41 mg/g, n = 5) when killed at 7 days after injection. Lastly, global heart function was analyzed by means of in vivo echocardiographic analysis of the left ventricular end diastolic and end systolic dimensions and fractional shortening. A global left ventricular ejection fraction was also calculated. As shown in Table 1 , no statistical difference could be found between the various groups of animals, thus confirming the good clinical tolerance achieved by this local method of gene delivery.
To optimize our injection protocol, we tested the efficiency of increasing doses of recombinant adenovirus . Three groups of animals were analyzed and all results are expressed as mean ± standard error. No significant modifications were observed in both treated groups compared with sham-operated rats. Sham-operated (Sham) animals received the complete permeabilizing mix without vector and were examined at day 7 after injection. Virus-injected animals were analyzed either at day 7 (D7) or at day 28 (D28).
ranging from 8 × 10 8 plaque forming unit (p.f.u.) to 4 × 10 10 p.f.u. As shown in Table 2 , the maximal efficiency of transduction was obtained with 8 × 10 9 p.f.u. Higher doses did not improve efficiency and were usually found to lead to premature death of the animals (data not shown). All further experiments were conducted using 8 × 10 9 p.f.u. We also determined the volume of virus which had to be used and found that the best results were obtained with an injection volume of 750 l. Above this volume, leakage outside the pericardium seems to dominate while below 500 l, diffusion of the vector around the heart is limited, thus resulting in a smaller area of transduction of the myocardium. 41.10 ± 6.62 0.0066
The influence of the total viral load was estimated by measuring the X-gal-stained area on transverse sections. Animals were killed at 6.5 days after injection. This planimetric methods which integrates adjacent areas may underestimate sparsely transfected myocardial cells, but is almost operator independent on successive sections. Results are expressed as mean ± standard error and were compared pairwise by statistical tools. A time-course analysis of transgene expression shows that, already at day 1, a significant expression of the transgene can be detected which increases until day 7 when 40.8 ± 7.3% (n = 8) of the myocardium is transfected by the adenovirus (Table 3) . Thereafter, transgene expression progressively declined due to a significant inflammatory reaction which was found around all areas expressing the transgene (data not shown). This timecourse correlates well with previous results reported on Gene expression in the myocardium was followed from day 1 to day 42 after injection. X-gal-stained areas were expressed as a percentage of the total transverse section area. Results are expressed as mean ± standard error. The evolution of this value was analyzed pairwise by statistical tools.
direct injection of adenoviral vectors into the myocardium, where transgene expression strongly increased during the first 7 days and then progressively declined at 14 and 21 days. 4 We did not try to immunosuppress our animals since our goal was not to look for long-term gene expression, but to establish the conditions which would allow an optimal viral transduction of the myocardium. It is well known that first generation adenoviral vectors induce an immune response that is a major cause of transient gene expression in immunocompetent animals and avoidance of an immune response may extend expression of genes introduced into the myocardium. 21, 22 Tissues other than the myocardium were routinely assayed for ␤-galactosidase activity. As anticipated, lung, liver, spleen and kidneys were always positive; however, the diaphragm muscle never showed evidence of transduction by the adenovirus, indicating that our transdiaphramatic injection did not induce any transfection of the diaphragm.
Our strategy is not limited to the rat, and Figure 4 shows that a comparable result can be obtained with C57BL/6 mice. The distribution of expression is similar to that found in the rat, especially with regard to the regions of the myocardium which are excluded such as the left ventricle (compare Figure 2 and Figure 4 ).
In conclusion, our results demonstrate that intra-pericardial injection of recombinant adenovirus vectors in the presence of proteolytic enzymes leads to an efficient and safe strategy to deliver a transgene to the heart. No damage to the global heart function could be detected by echocardiographic measurements nor could we find any significant structural alterations of the myocardium at this early stage. As anticipated, we subsequently observed an inflammatory reaction due to the immunogenic potential of both the adenovirus vector and the reporter gene. For future development of this strategy it is obvious that other vectors will need to be used which will include better tailored defective adenovirus or less immunogenic viruses such as the adeno-associated virus 23, 24 or even naked DNA. Moreover, the fact that other noncardiac tissues were also efficiently transduced emphasizes the need for another level of control. This will be achieved by placing the therapeutic gene under the control of a cardiac-specific promoter. Finally, the fact that we could transpose our method to another animal model and obtain similar results prompts us to suggest that this approach will be useful for future gene therapy in heart disease.
